Goldman Sachs Group Inc. Has $153.91 Million Stock Holdings in Sanofi $SNY

Key Points

• Goldman Sachs Group Inc. reduced its stake in Sanofi by 2.9%, owning 2,775,176 shares valued at approximately $153.9 million after selling 82,952 shares in the first quarter.
• Sanofi reported $0.90 earnings per share (EPS) for the last quarter, missing the consensus estimate of $0.96, while revenue was $11.34 billion, exceeding expectations.
• Various research firms, including Morgan Stanley and JPMorgan Chase & Co., recently upgraded Sanofi's ratings, reflecting growing investor confidence in the stock.

Goldman Sachs Group Inc. decreased its position in Sanofi (NASDAQ:SNY - Free Report) by 2.9% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 2,775,176 shares of the company's stock after selling 82,952 shares during the period. Goldman Sachs Group Inc. owned about 0.11% of Sanofi worth $153,911,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of SNY. Brighton Jones LLC grew its holdings in shares of Sanofi by 52.6% during the 4th quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock worth $261,000 after purchasing an additional 1,869 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Sanofi by 8.8% during the fourth quarter. Focus Partners Wealth now owns 71,808 shares of the company's stock valued at $3,483,000 after purchasing an additional 5,795 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Sanofi by 2.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,503 shares of the company's stock valued at $2,339,000 after acquiring an additional 1,235 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in shares of Sanofi by 1.0% during the 4th quarter. Nuveen Asset Management LLC now owns 3,676,224 shares of the company's stock valued at $177,304,000 after buying an additional 34,660 shares in the last quarter. Finally, Pathstone Holdings LLC boosted its position in shares of Sanofi by 22.5% in the fourth quarter. Pathstone Holdings LLC now owns 206,895 shares of the company's stock valued at $9,981,000 after acquiring an additional 37,937 shares during the period. Institutional investors own 14.04% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have weighed in on the stock. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a report on Tuesday, June 3rd. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Barclays reiterated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Finally, Morgan Stanley raised Sanofi from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $62.67.

Sanofi Trading Up 0.4%

SNY stock traded up $0.19 during midday trading on Wednesday, reaching $47.05. 668,861 shares of the company's stock traded hands, compared to its average volume of 2,588,050. The business has a 50-day moving average price of $48.58 and a two-hundred day moving average price of $51.03. The company has a market capitalization of $115.53 billion, a P/E ratio of 11.33, a PEG ratio of 1.10 and a beta of 0.51. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.73 EPS. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.